Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 8/20 | 0.40 |
| ▸ | HTR6 | P50406 | 3/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | PSD | A5PKW4 | 3/20 | 0.37 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25463926 | 0.86 | CLK1 (0.41) | PIM1PSDCLK1DYRK1AADORA2A | |
| SCHEMBL23925576 | 0.86 | CLK1 (0.41) | PIM1PSDCLK1DYRK1AADORA2A | |
| SCHEMBL23925577 | 0.86 | CLK1 (0.41) | PIM1PSDCLK1DYRK1AADORA2A | |
| SCHEMBL23416866 | 0.84 | MTOR (0.41) | PSDCLK1DYRK1AADORA2AADORA1 | |
| SCHEMBL26280652 | 0.84 | MTOR (0.41) | PSDCLK1DYRK1AADORA2AADORA1 | |
| SCHEMBL23950535 | 0.84 | CLK1 (0.38) | PIM1PSDCLK1DYRK1AADORA2A | |
| SCHEMBL25463141 | 0.84 | CLK1 (0.38) | PIM1PSDCLK1DYRK1AADORA2A | |
| SCHEMBL23950537 | 0.84 | CLK1 (0.38) | PIM1PSDCLK1DYRK1AADORA2A | |
| SCHEMBL23950775 | 0.84 | MAPK14 (0.44) | PIM1HTR6BRD4CLK1DYRK1A | |
| SCHEMBL23390140 | 0.84 | KCNH2 (0.41) | PIM1PSDADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295152-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS | SENDA BIOSCIENCES, INC. (US) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295152-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS | AHR, ARNT, AIPL1 | PIM1 2854/4885HTR6 392/4885BRD4 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.